BridgeBio Pharma announced strategic financing from Blue Owl Capital and CPP Investments, bringing in capital of up to $1.25 billion.
BridgeBio Pharma, a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced strategic financing from Blue Owl Capital and CPP Investments, through a wholly owned subsidiary of CPPIB Credit Investments Inc., bringing in capital of up to $1.25 billion.…